Patents by Inventor Magdalena Milczarek

Magdalena Milczarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE
    Publication number: 20230069886
    Abstract: The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small molecule inhibitors of PDI A3 that display antiplatelet, antithrombotic and anticancer activities.
    Type: Application
    Filed: January 10, 2020
    Publication date: March 9, 2023
    Inventors: Stefan CHLOPICKI, Ivars KALVINS, Kamil PRZYBOROWSKI, Marta STOJAK, Victor ANDRIANOV, Ilona DOMRACEVA, Iveta KANEPE-LAPSA, Diana ZELENCOVA, Joanna WIETRZYK, Eliza TURLEJ, Martyna STACHOWICZ, Joanna JAROSZ, Magdalena MILCZAREK, Karol KRAMKOWSKI
  • AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE
    Publication number: 20230039836
    Abstract: The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small molecule inhibitors of PDI A1 that display antiplatelet, antithrombotic and anticancer activities.
    Type: Application
    Filed: January 10, 2020
    Publication date: February 9, 2023
    Inventors: Ivars KALVINS, Stefan CHLOPICKI, Marta STOJAK, Victor ANDRIANOV, Ilona DOMRACEVA, Iveta KANEPE-LAPSA, Diana ZELENCOVA, Joanna WIETRZYK, Eliza TURLEJ, Martyna STACHOWICZ, Joanna JAROSZ, Magdalena MILCZAREK, Karol KRAMKOWSKI
  • COMBINED THERAPY OF COLORECTAL CARCINOMA
    Publication number: 20120101057
    Abstract: The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from a group consisting of tacalcitol, calcipotriol and 5,6-trans-isomer of calcipotriol.
    Type: Application
    Filed: June 9, 2010
    Publication date: April 26, 2012
    Applicant: INSTYTUT FARMACEUTYCZNY
    Inventors: Joanna Wietrzyk, Magdalena Milczarek, Andrzej Kutner, Michal Chodynski